Becaplermin gel

Drug Profile

Becaplermin gel

Alternative Names: PGDF-B; Recombinant human platelet-derived growth factor-beta; Regranex; RWJ 60235

Latest Information Update: 28 Sep 2013

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Johnson & Johnson; ZymoGenetics
  • Class Blood proteins; Cicatrizants; Growth factors; Recombinant proteins
  • Mechanism of Action Platelet-derived growth factor receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Marketed Diabetic foot ulcer
  • Discontinued Pressure ulcer; Varicose ulcer

Most Recent Events

  • 25 Sep 2013 Healthpoint Biotherapeutics is now called Smith & Nephew Biotherapeutics
  • 21 Dec 2012 Healthpoint Biotherapeutics has been acquired by Smith & Nephew
  • 03 Jun 2011 Healthpoint Biotherapeutics acquires becaplermin gel from Systagenix Wound Management
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top